Acurx Pharmaceuticals, Inc. (ACXP): R&D Expense
$1.83M
Year ended 2025-12-31
$2.12M
Trailing 12 months to 2026-06-30
-27.2%
3-year compound annual growth
-3.6%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.83M | -66.1% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $5.40M | -10.6% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $6.04M | +27.1% | 2025-03-17, From 2023-01-01 |
| 2022-12-31 | $4.75M | +134.2% | 2024-03-15, From 2022-01-01 |
| 2021-12-31 | $2.03M | -7.8% | 2023-03-15, From 2021-01-01 |
| 2020-12-31 | $2.20M | n/a | 2022-03-16, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Acurx Pharmaceuticals, Inc. (ACXP) | 2025-12-31 | $1.83M | -66.1% |
| Silo Pharma, Inc. (SILO) | 2025-12-31 | $2.16M | -8.8% |
| Rocket One Inc. (RKTO) | 2025-12-31 | $5.95M | +83.0% |
| Oncolytics Biotech Inc (ONCY) | 2025-12-31 | $13.31M | -13.8% |
| Processa Pharmaceuticals, Inc. (PCSA) | 2025-12-31 | $7.81M | +7.4% |
| Dermata Therapeutics, Inc. (DRMA) | 2025-12-31 | $2.93M | -64.3% |
| Ensysce Biosciences, Inc. (ENSC) | 2025-12-31 | $10.38M | +43.7% |
| Telomir Pharmaceuticals, Inc. (TELO) | 2025-12-31 | $2.44M | +9.0% |
| GT Biopharma, Inc. (GTBP) | 2025-12-31 | $3.47M | -40.1% |
Compare ACXP, SILO, RKTO, ONCY side by side · Screen every company in Pharmaceutical Preparations ↗